Tags

Type your tag names separated by a space and hit enter

A Review of Remdesivir for COVID-19: Data to Date.
Cardiol Rev. 2020 Nov/Dec; 28(6):332-334.CR

Abstract

Severe acute respiratory coronavirus-2 (SARS-CoV-2) is responsible for one of the greatest public health challenges of our lifetime, the coronavirus disease 2019 (COVID-19) pandemic. Because of the complicated postinfection sequelae and grave consequences, the search for effective therapies has become a worldwide priority. The antiviral agent remdesivir has become a viable option and is now available in the United States for hospitalized patients through an emergency use authorization. This article describes remdesivir's historical background, pharmacology, key trials, adverse events, and issues regarding accessibility.

Authors+Show Affiliations

From the Department of Pharmacy, New York-Presbyterian Hospital, New York, NY.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32773440

Citation

Mehta, Monica, and Grace I. Shyh. "A Review of Remdesivir for COVID-19: Data to Date." Cardiology in Review, vol. 28, no. 6, 2020, pp. 332-334.
Mehta M, Shyh GI. A Review of Remdesivir for COVID-19: Data to Date. Cardiol Rev. 2020;28(6):332-334.
Mehta, M., & Shyh, G. I. (2020). A Review of Remdesivir for COVID-19: Data to Date. Cardiology in Review, 28(6), 332-334. https://doi.org/10.1097/CRD.0000000000000337
Mehta M, Shyh GI. A Review of Remdesivir for COVID-19: Data to Date. Cardiol Rev. 2020 Nov/Dec;28(6):332-334. PubMed PMID: 32773440.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Review of Remdesivir for COVID-19: Data to Date. AU - Mehta,Monica, AU - Shyh,Grace I, PY - 2020/8/11/pubmed PY - 2020/10/21/medline PY - 2020/8/11/entrez SP - 332 EP - 334 JF - Cardiology in review JO - Cardiol Rev VL - 28 IS - 6 N2 - Severe acute respiratory coronavirus-2 (SARS-CoV-2) is responsible for one of the greatest public health challenges of our lifetime, the coronavirus disease 2019 (COVID-19) pandemic. Because of the complicated postinfection sequelae and grave consequences, the search for effective therapies has become a worldwide priority. The antiviral agent remdesivir has become a viable option and is now available in the United States for hospitalized patients through an emergency use authorization. This article describes remdesivir's historical background, pharmacology, key trials, adverse events, and issues regarding accessibility. SN - 1538-4683 UR - https://www.unboundmedicine.com/medline/citation/32773440/A_Review_of_Remdesivir_for_COVID_19:_Data_to_Date_ L2 - https://doi.org/10.1097/CRD.0000000000000337 DB - PRIME DP - Unbound Medicine ER -